Amarin Corp Plc (AMRN)

[ziploc_1]

Rose..." But we'll have to see where the price of Vascepa monotherapy will be at the time of launch because that's going to be very determining whether we launch or not in the US."

I Think what KM was implying was....that, if all else fails and if the generics succeed in stealing the Vascepa market in the U.S....and compel Amarin to issue an authorized generic Vascepa as a mono drug in order to survive as a a company, we will be forced to skirt the U.S. market and issue the statin-Vascepa combo drug in Europe alone.